Identification and Characterization of a Mitochondrial Targeting Signal in Rat Cytochrome P450 2E1 (CYP2E1)*

Etienne P. A. Neve and Magnus Ingelman-SundbergDagger

From the Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, S-171 77 Stockholm, Sweden

Received for publication, September 21, 2000, and in revised form, December 19, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cytochrome P450 2E1 (CYP2E1) lacking the hydrophobic NH2-terminal hydrophobic transmembrane domain is specifically targeted to mitochondria, where it is processed to a soluble and catalytically active form (Delta 2E1) with a mass of about 40 kDa. Small amounts of Delta 2E1 were also observed in mitochondria isolated from rat liver, indicating that this form of CYP2E1 is also present in vivo. In the present study the mitochondrial targeting signal was identified and characterized by the use of several NH2-terminally truncated and mutated forms of CYP2E1 that were expressed in the mouse H2.35 hepatoma cell line. Two potential mitochondrial targeting sequences were identified in the NH2 terminus of CYP2E1. Deletion of the first potential mitochondrial targeting sequence located between amino acids 50 and 65, as in Delta (2-64)2E1, still resulted in mitochondrial targeting and processing, but when, in addition to the first, the second potential mitochondrial targeting sequence located between amino acids 74 and 95 was also deleted, as in Delta (2-95)2E1, the mitochondrial targeting was abolished. Mutation of the four positively charged Arg and Lys residues present in this sequence to neutral Ala residues resulted in the abrogation of mitochondrial targeting. Deletion of a hydrophobic stretch of amino acids between residues 76 and 83 also abolished mitochondrial targeting and import. Once imported in the mitochondria, these constructs were further processed to the mature protein Delta 2E1. It is concluded that mitochondrial targeting of CYP2E1 is mediated through a sequence located between residues 74 and 95 and that positively charged residues as well as a hydrophobic stretch present in the beginning of this sequence are essential for this process.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The majority of the mitochondrial proteins are encoded from nuclear DNA, synthesized in the cytosol as precursors and posttranslationally targeted to the mitochondria (1-3). Many of the proteins that are destined for import into the mitochondrial matrix contain a signal sequence in their NH2 terminus that directs these proteins to the mitochondria (4), although these signal sequences are also found in the COOH terminus of the protein (5, 6). Despite the fact that there is no general consensus for mitochondrial matrix targeting sequences, many of these sequences were demonstrated to be rich in positively charged and hydrophobic amino acid residues and usually are able to form an amphiphilic secondary structure (7, 8). The mitochondrial matrix targeting sequence initially interacts with the import receptor (Tom20) that is part of the translocase of the outer membrane (TOM)1 complex present in the mitochondrial outer membrane (9, 10). The surface of Tom20, which is rich in negatively charged amino acid residues, is thought to recognize and bind the positively charged residues present in these signal sequences; however, additional binding forces such as hydrophobic interactions also play an important role (10). After binding, the protein is then allowed to cross the lipid bilayer through the general translocation pore formed by the TOM complex (11). Proteins destined for the matrix are then transferred to the translocase of the inner membrane (TIM) complex and translocated into the matrix space (12, 13), where the NH2-terminal signal sequence of the protein is proteolytically removed by proteases present in the matrix (14, 15).

The NH2-terminal hydrophobic transmembrane domain of microsomal cytochrome P450s (P450s) was shown not only to be responsible for the cotranslational targeting in a signal recognition particle (SRP)-dependent manner to the endoplasmic reticulum (ER) membrane (16, 17), but also to be responsible for anchoring and retention in the ER membrane (18, 19). Not all P450 enzymes are retained in the ER membrane by the same mechanisms; as was recently demonstrated, CYP2C1 is retained by static retention preventing exit from the ER, while CYP2E1 is retained by a retrieval mechanism allowing it to be recycled back from post-ER compartments (20, 21). In contrast to microsomal P450s, mitochondrial P450s are, like most of the nuclear encoded mitochondrial proteins, posttranslationally targeted to mitochondria by means of their amphiphilic NH2-terminal signal sequence (22, 23).

Cytochrome P450 2E1 (CYP2E1) is the alcohol-inducible member of the P450 family and has been suggested to be involved in gluconeogenesis because of its ability to metabolize ketone bodies such as acetone (24, 25). In addition, a wide variety of small hydrophobic xenobiotics including many well known carcinogenic and toxic compounds are metabolized by CYP2E1 (24). CYP2E1 is also known for its ability to cause oxidative stress that could ultimately lead to apoptosis (26) and to alcoholic liver disease (27, 28).

Although CYP2E1 is predominantly located in the membrane of the ER, it has also been demonstrated to be present in lysosomes (29), peroxisomes (30), Golgi apparatus (31), and on the outer surface of the plasma membrane (32, 33). Previously we reported that an NH2-terminally truncated form of CYP2E1 was specifically targeted to the mitochondria (34). Deletion or mutation of the NH2-terminally hydrophobic transmembrane domain of CYP2E1 resulted in the mitochondrial localization of the protein when these constructs were transiently expressed in a mouse hepatoma cell line. It was demonstrated that this mitochondrially localized form of CYP2E1 was a NH2-terminally truncated form of CYP2E1 of ~40 kDa named Delta 2E1, which was shown to be soluble, catalytically active, and localized inside the mitochondria. In addition, Delta 2E1 was present in low levels in vivo in mitochondria isolated from rat liver.

In the present investigation, the mitochondrial targeting sequence of CYP2E1 was identified by constructing several NH2-terminal deletion mutants of CYP2E1, which lacked one or both putative mitochondrial targeting sequences that are present in the NH2 terminus of CYP2E1. Moreover, the role of the positively charged and hydrophobic amino acid residues present in this sequence in the mitochondrial targeting was investigated by mutational analysis.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression Vectors-- The CYP2E1 cDNAs encoding the truncated CYP2E1 variants Delta (2-29)2E1, Delta (2-64)2E1, Delta (2-76)2E1, Delta (2-82)2E1, and Delta (2-95)2E12 were generated by polymerase chain reaction amplification using Pfu DNA polymerase (Stratagene, La Jolla, CA), the appropriate sense primer containing an ATG codon, primers 1a, 1b, 1c, 1d, and 1e, respectively (Table I); the wild-type antisense primer 2a; and CYP2E1 cDNA as a template. The RKright-arrowA cDNA containing the internal mutations R75A, R76A, K84A, and K87A and the Kright-arrowA cDNA containing K84A and K87A were generated by polymerase chain reaction amplification using the sense primers starting from position 193 (corresponding to amino acid position 65) that incorporated the mutations, primer 1f for RKright-arrowA and primer 1g for Kright-arrowA, the wild-type antisense primer 2a, and CYP2E1 cDNA as a template. The resulting cDNAs were cloned between the EcoRI and XbaI sites of the mammalian pCMV5 expression vector. The constructs R75A and RRright-arrowAA were prepared as follows. The pCMV5 vector contains a unique BsgI restriction site located outside the cloning box, 235 bases 3' of the XbaI site, and CYP2E1 cDNA also has a unique BsgI restriction site at position 213. The vector containing the insert Delta (2-29)2E1 was digested with BsgI, thereby cutting out the Delta (2-29)2E1 cDNA from position 127 until the BsgI site after the cloning box, thereby leaving the first 126 5' bases of Delta (2-29)2E1 attached to the vector. The CYP2E1 cDNAs containing the mutations were generated by polymerase chain reaction amplification using the sense primer containing a BsgI site and the appropriate mutations, primer 1h for R75A and primer 1i for RRright-arrowAA, the antisense primer that anneals just after the BsgI site of the vector primer 2b, and pCMV-CYP2E1 as a template. The resulting cDNA fragments were cloned in between the two BsgI sites of pCMV5 vector still containing the cDNA coding for the first amino acids of the construct. The correct sequences of all inserts were confirmed by DNA sequencing using the ABI PRISM® dye terminator cycle sequencing kit from PerkinElmer Life Sciences.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Sequences of the oligonucleotides used as polymerase chain reaction primers
The nucleotides coding for the bases that were mutated are represented in a boldface type, and the recognition sites for the restriction enzymes are depicted in italics.

Cell Culture, Transient Transfection, and Western Blotting-- H2.35 cells were grown and transfected as described (33, 34). Western blot analysis was performed as described (31) and immunoreactive bands were visualized using the Fuji Las-1000 luminescent image analyzer (Fujifilm, Sweden).

Immunofluorescent Microscopy-- After transfection, the H2.35 cells were fixed and processed for immunostaining as described (33, 34). Transfected proteins were detected by using CYP2E1-specific antibodies and visualized by anti-rabbit fluorescein isothiocyanate-conjugated antibodies. Cells were double-immunostained by sequential incubation with CYP2E1-specific rabbit polyclonal antibodies, which were visualized by anti-rabbit fluorescein isothiocyanate-conjugated antibodies, followed by incubation with mitochondrial heat shock protein 70 (mHsp70)-specific monoclonal antibodies (Affinity Bioreagents Inc., Goldon, CO), which were visualized by anti-mouse tetramethyl rhodamine isothiocyanate-conjugated antibodies. Cells were viewed under a Nikon Eclipse E600 fluorescent microscope equipped with a camera using the 60× oil immersion objective.

Catalytic Activity-- The catalytic activity of several of the CYP2E1 variants was determined by monitoring the hydroxylation of chlorzoxazone (31, 34). The post-nuclear supernatant of cells transfected with Delta (2-29)2E1, Delta (2-64)2E1, Delta (2-95)2E1, or empty plasmid was prepared, and organelles were disrupted by sonication (three bursts of 10 s with 30-s intervals) on ice. Mitochondria were isolated from cells transfected with empty plasmid or Delta (2-29)2E1 and disrupted by sonication as described previously (34). The incubation mixture consisted of 250 µg of sonic disrupted post-nuclear supernatant or 100 µg of sonic disrupted mitochondria, 50 µM chlorzoxazone, a NADPH generating system (0.2 mM NADPH, 2.0 mM glucose 6-phosphate, and 3 units/ml glucose-6-phosphate dehydrogenase) and 50 mM phosphate buffer, pH 7.4, in a final volume of 250 µl in the presence or absence of 1.0 nmol of adrenodoxin (Adx), 0.1 nmol of adrenodoxin reductase (AdR), kindly supplied by Prof. Rita Bernhardt (University of Saarbrücken, Germany). After 30 min of incubation at 37 °C, the reaction was terminated by the addition of orthophosphoric acid, and samples were extracted and analyzed on an Varian ProStar HPLC system (Varian, Walnut Creek, CA) equipped with an amperometric detector (Bioanalytical Systems Inc, West Lafayette, IN).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The mitochondrial targeting of a NH2-terminally truncated form of CYP2E1, Delta (2-29)2E1, was investigated by constructing several NH2-terminal deletion mutants of CYP2E1 (see Fig. 1). Examination of the first 100 amino acids of CYP2E1 revealed that there are two amino acid stretches that could serve as potential mitochondrial targeting signals (the underlined sequences shown in Fig. 1). Both these sequences are rich in positively charged and hydrophobic amino acids and are potentially able to form an amphiphilic secondary structure, features that are characteristic for a mitochondrial targeting signal.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 1.   NH2-terminal amino acid sequence of the CYP2E1 constructs used in this study. The potential mitochondrial targeting sequences are underlined, and the hydrophobic transmembrane domain is represented in a box. The positively charged amino acid residues that were mutated are depicted in a gray box and mutated residues in a black box.

H2.35 cells transfected with Delta (2-29)2E1 were analyzed by Western blotting and a NH2-terminally truncated form of CYP2E1 of around 40 kDa named Delta 2E1 (Fig. 2) was detected (34). Subcellular localization by immunofluorescent microscopy confirmed the mitochondrial localization of Delta 2E1 (Fig. 3). Indeed, the staining pattern observed using CYP2E1-specific antibodies (Fig. 4, upper left panel) was identical to that observed using antibodies recognizing the mitochondrial protein, mHsp70 (Fig. 4, upper right panel). To identify the targeting sequence that was responsible for the mitochondrial targeting and import, two constructs were designed that lacked one or both potential targeting sequences. Delta (2-64)2E1, in which the first potential targeting signal (amino acids 51-64) was deleted, was transfected into H2.35 cells, which were analyzed by Western blotting. In addition to Delta 2E1, a protein with the expected full length of the construct was observed (Fig. 2), and both these proteins were recovered in the mitochondrial fraction (data not shown). Immunofluorescent microscopy demonstrated that cells transfected with Delta (2-64)2E1 displayed a similar staining pattern to that observed for Delta (2-29)2E1-transfected cells (Fig. 3) and was shown to colocalize with mHsp70 (Fig. 4), confirming its mitochondrial localization. These results clearly demonstrated that deletion of the first 64 amino acids of CYP2E1 did not affect the mitochondrial targeting and that the region between amino acids 51 and 64 was not responsible for directing Delta (2-29)2E1 to the mitochondria.



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of the NH2-terminally truncated and mutated CYP2E1 variants in mouse H2.35 cells. The post-nuclear supernatants of the transfected cells were analyzed by Western blotting using CYP2E1-specific antibodies. The arrows indicate Delta 2E1, the mature form that is present in the mitochondria. Asterisks indicate proteins that correspond to the full length of the various constructs.



View larger version (72K):
[in this window]
[in a new window]
 
Fig. 3.   Subcellular localization of the NH2-terminally truncated and mutated CYP2E1 constructs assessed by immunofluorescent microscopy when expressed in H2.35 cells. After transfection cells were fixed, permeabilized, and incubated with CYP2E1-specific antibodies and visualized with anti-rabbit fluorescein isothiocyanate-conjugated antibodies.



View larger version (41K):
[in this window]
[in a new window]
 
Fig. 4.   Mitochondrial localization of Delta (2-29)2E1, Delta (2-64)2E1, Delta (2-76)2E1, Kright-arrowA, R75A, and RRright-arrowAA. H2.35 cells transfected with the various CYP2E1 constructs were coimmunostained with CYP2E1-specific antibodies, which were visualized with anti-rabbit fluorescein isothiocyanate-conjugated antibodies (left panels), and with the mitochondrial protein mHsp70-specific antibodies, which were visualized with anti-mouse tetramethyl rhodamine isothiocyanate-conjugated antibodies (right panels).

Delta (2-95)2E1, in which in addition to the first potential mitochondrial targeting signal, also the second potential targeting sequence between amino acids 75 and 95 was deleted, was expressed in H2.35 cells. A protein with a slightly lower mobility than Delta 2E1 was observed by Western blotting (Fig. 2), which corresponds to the expected full-length size of the construct. Immunofluorescent microscopy demonstrated that Delta (2-95)2E1 was not associated with the mitochondria, but instead displayed a diffuse staining pattern throughout the whole cell, most likely representing a cytosolic localization of this protein (Fig. 3). These data demonstrated that the region between amino acids 74 and 95 was responsible for the mitochondrial targeting and that this region served as a mitochondrial targeting signal.

Previously we showed that Delta 2E1 was catalytically active in the presence of the mitochondrial electron carrier proteins Adx and AdR (34). The post-nuclear supernatant of cells transfected with Delta (2-29)2E1, Delta (2-64)2E1, and Delta (2-95)2E1 was assayed for catalytic activity (Fig. 5A). As expected, cells transfected with Delta (2-29)2E1 displayed catalytic activity in the presence of both Adx and AdR. Additionally, cells transfected with Delta (2-64)2E1 had significant chlorzoxazone hydroxylation activity with levels well over those of cells transfected with empty plasmid (mock). When incubated in the absence of Adx and AdR, no significant increase in catalytic activity was observed, indicating that these truncated CYP2E1 variants were not able to couple with the endogenous NADPH cytochrome P450 reductase. Despite the extensive deletion in Delta (2-95)2E1, some residual catalytic activity could still be detected, although the observed levels were very low. The expression levels of these three truncated proteins were found to be very similar (see Fig. 2), which indicated that only a part of the Delta (2-95)2E1 expressed was catalytically active. Mitochondria isolated from cells transfected with Delta (2-29)2E1 displayed a 3-fold increase in catalytic activity over mitochondria isolated from mock transfected cells (Fig. 5B), indicating that the catalytic activity is associated with the mitochondria as was also previously reported (34).



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Catalytic activity of the NH2-terminally truncated CYP2E1 variants. A, the post-nuclear supernatant isolated from H2.35 cells transfected with empty plasmid (Mock), Delta (2-29)2E1, Delta (2-64)2E1, and Delta (2-95)2E1 was assayed in the absence (solid bars) or presence (gray bars) of both Adx and AdR for the formation of 6-hydroxychlorzoxazone (6-OH-CZN) as described under "Experimental Procedures." B, mitochondria isolated from H2.35 cells transfected with empty plasmid (mock) and Delta (2-29)2E1 were assayed in the presence of Adx and AdR for the formation of 6-hydroxychlorzoxazone. The levels measured in the mitochondria isolated from mock transfected cells was arbitrarily set at 100%. Data are represented as mean ± S.E. The numbers in parentheses at the bottom of the graph indicate the number of individual determinations. Significant differences are indicated by an asterisk (p < 0.05).

The involvement of the positively charged residues that are present in the mitochondrial targeting sequence identified above, Arg at positions 75 and 76 and Lys at positions 84 and 87, was studied by mutating all four these residues to uncharged Ala residues, mutant RKright-arrowA. Western blotting revealed that only the full length of the construct was expressed in cells transfected with RKright-arrowA; no Delta 2E1 protein could be observed (Fig. 2). The subcellular localization was shown to be similar to cells transfected with Delta (2-95)2E1, a diffuse staining pattern indicative of a cytoplasmic localization (Fig. 3). This showed that together these four positively charged residues present in the mitochondrial targeting signal are essential for the mitochondrial targeting and subsequent import of this protein. In addition, the data hitherto presented demonstrate that, once the protein is imported into the mitochondria, the mitochondrial import signal is removed thus forming the mature protein Delta 2E1.

Mutation of only the two Lys residues to Ala (Kright-arrowA) caused decreased, although significant mitochondrial import and processing (Fig. 2). Thus, most of the protein expressed was the full-length construct (unprocessed form), whereas a significantly smaller amount was found to be truncated to Delta 2E1. When Kright-arrowA-transfected cells were examined by immunofluorescent microscopy, two populations of staining patterns were observed (Fig. 3), some cells displayed typical mitochondrial staining, which was confirmed by colocalization with mHsp70 (Fig. 4), while others had a more diffuse staining pattern resembling the staining observed for RKright-arrowA.

Mutation of only the two positive Arg residues to the uncharged Ala residues (RRright-arrowAA) had no effect on the mitochondrial localization of Delta (2-29)2E1 (Figs. 3 and 4). Unfortunately, because of the low levels of expression of RRright-arrowAA, analysis by Western blot proved to be difficult. These data indicated no absolute requirement for these two residues alone in the mitochondrial targeting. When Arg-75 was mutated to the hydrophobic residue Ile and Arg-76 mutated to Ala (RRright-arrowIA), a similar subcellular distribution as for RRright-arrowAA was observed. In addition, Western blot analysis revealed that these transfected cells expressed Delta 2E1, indicating that mitochondrial targeting and import was not affected by these mutations (data not shown). Additionally, substitution of Arg-75 with Ala (R75A) had no effect on the mitochondrial targeting and processing, the transfected cells expressed Delta 2E1 (Fig. 2) and displayed the typical mitochondrial staining pattern (Figs. 3 and 4). These results indicated that the two Arg residues at positions 75 and 76 alone were not essential for the mitochondrial targeting and import of Delta (2-29)2E1.

Partial disruption of the mitochondrial targeting signal as in Delta (2-76)2E1 and Delta (2-82)2E1 resulted in low expression levels that were difficult to detect by Western blot analysis. The few transfected cells were, however, easily detected by immunofluorescent microscopy. Some of the cells transfected with Delta (2-76)2E1, in which the NH2 terminus including Arg-75 and Arg-76 was deleted, displayed the typical mitochondrial staining pattern, while others had a more diffuse staining pattern, a pattern similar to that observed for Kright-arrowA-transfected cells (Figs. 3 and 4). This was in good agreement with the results obtained above, which showed that Arg-75 and Arg-76 had only a minor effect on mitochondrial targeting. Further disruption of the mitochondrial targeting signal as in Delta (2-82)2E1 resulted in the diffuse cytoplasmic staining pattern in cells transfected with this construct, indicating that the hydrophobic region between amino acids 76 and 83 was essential for the mitochondrial targeting of Delta (2-29)2E1 (Fig. 3).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The hydrophobic NH2 terminus of P450s is responsible for the cotranslational targeting of the protein to the membrane of the ER (16, 17). Deletion of the hydrophobic ER targeting signal as in Delta (2-29)2E1 results in targeting of this truncated protein to the mitochondria (34). In the present study, it was demonstrated, by sequential deletion of the NH2 terminus and by mutational analysis, that the region between amino acids 74 and 95 is responsible for the mitochondrial targeting of CYP2E1. The presence of four positively charged amino acid residues as well as a stretch of hydrophobic residues at the beginning of this targeting sequence were shown to be essential for the mitochondrial targeting and import of Delta (2-29)2E1. Western blot analysis showed that Delta 2E1 displayed a slightly higher mobility than Delta (2-95)2E1, suggesting that Delta 2E1 is a NH2-terminally truncated form of CYP2E1 lacking approximately the first 100 amino acids.

It is well known that many of the proteins that are targeted to mitochondria contain a mitochondrial targeting signal, also called a presequence, which is usually located at the NH2 terminus of the protein (1-4). Attempts to define a general consensus sequence for these mitochondrial targeting signals have not resulted in a well defined motif as is known for proteins targeted to other intracellular organelles such as peroxisomes (35) or the endocytic compartment (36). General features valid for most of the mitochondrial targeting sequences are that they are usually rich in positively charged and hydrophobic amino acid residues, they do not contain any or very few negatively charged residues, and they have the potential to form an amphiphilic secondary structure (7, 8, 37). It is believed that the positively charged residues together with the hydrophobic residues are essential for binding to the negatively charged surface of the Tom20 receptor (10, 11). Recently, however, NMR studies have shown that the initial interaction between the signal sequence of rat aldehyde dehydrogenase and the rat Tom20 receptor was entirely mediated by hydrophobic interactions (38). The initial binding was shown not to be dependent on ionic interactions, thereby reducing the role for the positively charged residues of the presequence in the initial binding. This agreed well with the observation made in the present study; the hydrophobic region at the beginning of the mitochondrial targeting signal (amino acids 77-82) of CYP2E1 is essential for targeting to and import into the mitochondria. The positive charges of the presequence were shown to be important for transport across the mitochondrial outer and inner membrane by sequential binding to several components of the TOM and TIM complex (the "acid chain hypothesis") (11-13) and also are thought to be necessary for recognition by the mitochondrial processing peptidase (39).

Mutation of all four positively charged residues present in the mitochondrial targeting signal of CYP2E1 to uncharged Ala residues effectively prevented mitochondrial targeting and subsequent import as shown by both immunofluorescent microscopy and Western blot analysis. However, mutation of only one or both Arg residues at the beginning of this signal did not have any major effect on the mitochondrial targeting and import. Mutation of only the two Lys residues resulted in an intermediate result; although mitochondrial targeting and import was still observed, it was less efficient as compared with the construct Delta (2-64)2E1 where the two Lys residues were still present. Deletion of the NH2 terminus until just after the two Arg residues, as in Delta (2-76)2E1, still resulted in mitochondrial targeting, although less efficient, indicating that these Arg residues are not essential for mitochondrial targeting and import. These results implied that all four positively charged residues together are essential for mitochondrial targeting, and subsequent import and processing of Delta (2-29)2E1. The construct Delta (2-82)2E1, where, in addition to the two Arg residues, a hydrophobic stretch of amino acids was deleted, displayed a similar staining pattern as observed for Delta (2-95)2E1, i.e. a cytosolic localization. This strongly suggests that the hydrophobic region between Arg-76 and Lys-84 is critical for the mitochondrial targeting of Delta (2-29)2E1.

Despite the fact that Delta (2-95)2E1 displayed catalytic activity, it was lower than that observed in cells transfected with Delta (2-29)2E1 and Delta (2-64)2E1, which expressed Delta 2E1. In addition, it was further demonstrated that the catalytic activity is localized in the mitochondria. These data suggest that to efficiently assemble a catalytically active Delta 2E1 the folding and processing machinery present in the mitochondrial matrix is required. It should, however, be emphasized that the observed activities as well as the protein expression levels are very low when compared with those observed for wild-type CYP2E1. The demonstration that the catalytic activity is associated with isolated mitochondria, together with the observation that all the mitochondrial localized CYP2E1 variants are processed to the mature Delta 2E1, strongly indicates that Delta 2E1 is present in the mitochondrial matrix.

The results obtained in the present study allow the construction of a model that can explain the mitochondrial targeting of CYP2E1, where binding of the SRP and subsequently the cotranslational targeting pathway has been compromised by either deletion or mutation of the hydrophobic NH2-terminal transmembrane domain. The translation of CYP2E1 is normally initiated on ribosomes present in the cytosol and binding of the SRP to the hydrophobic NH2 terminus arrests this translation as soon as the nascent chain emerges from the ribosome (16, 17, 40). Translation only commences when the arrested complex is properly docked to the translocation complex present in the membrane of the ER (40). Deletion or modification of the hydrophobic NH2 terminus of CYP2E1 compromises the binding of the SRP, resulting in the translation of the entire protein on the cytosolic ribosomes. After synthesis, these proteins are most likely bound by cytosolic chaperones, targeted to the mitochondria by the exposed mitochondrial targeting sequence located between residues 74 and 95. After interaction with the TOM and TIM complex, CYP2E1 is translocated into the matrix of the mitochondria were the presequence is removed by the mitochondrial processing peptidase resulting in the mature protein, Delta 2E1.

Analysis of the secondary structure of the region of CYP2E1 between amino acids 74 and 95 revealed that the region from 83 to 95 was able to form an alpha -helical structure, while the region from 76 to 80 preferentially forms a beta -sheet. The presence of the alpha -helical part alone is not sufficient for targeting of Delta (2-29)2E1 to the mitochondria. Deletion of the hydrophobic part between residues 76 and 83 abolished the mitochondrial targeting as observed for Delta (2-82)2E1, emphasizing the importance of this hydrophobic stretch in the initial targeting and binding of the protein to the mitochondria. It can be suggested that, for the alpha -helical structure to bind to the hydrophobic groove present in the Tom20 receptor, an initial interaction of the hydrophobic residues located between residues 76 and 83 is necessary for the binding of the presequence to the mitochondrial import receptor. After proper binding of the presequence to Tom20, the presence of the positively charged amino acid residues becomes important for the actual translocation over the outer and inner membrane of the mitochondria and also for the interaction with the proteolytic and folding machinery in the mitochondrial matrix.

A model has been proposed for the mitochondrial targeting of an NH2-terminally truncated form of CYP1A1 expressed in both beta -naphthoflavone-induced rat liver and transiently in COS cells (41). By using an in vitro translation assay in the presence or absence of canine pancreatic microsomes and isolated rat liver cytosolic proteins, it was suggested that up to 25% of the nascent chains were able to escape cotranslational insertion into the ER membrane. It was further suggested that these escaped chains were processed by a cytosolic endopeptidase, resulting in the exposure of a mitochondrial targeting signal that directed the truncated CYP1A1 to the mitochondria. Our data, however, do not support this hypothesis; previous results showed that, when wild-type CYP2E1 was transfected in H2.35 cells, no mitochondrially localized Delta 2E1 could be detected, although the expression levels were significantly higher than for the constructs used in the present study (34). Only removal, as in Delta (2-29)2E1, or modification, as in N++2E1, of the hydrophobic NH2-terminal transmembrane domain of CYP2E1 resulted in mitochondrial targeting. Small amounts of Delta 2E1 were detected in isolated rat liver mitochondria suggesting that in vivo the fidelity of the SRP binding and cotranslational targeting pathway can be compromised.

Cyclic AMP-dependent phosphorylation of CYP2B1 at serine 128 was demonstrated to cause mitochondrial targeting of this phosphorylated protein (42). It was shown by using an in vitro translation system that phosphorylation of CYP2B1 interfered with the binding of the SRP and subsequent insertion into the ER membrane. Additionally, CYP2E1 has a serine at position 129 that can be phosphorylated in a cAMP-dependent manner, a modification that has been proposed to be involved in the degradation process (43). No mitochondrial targeting could be observed when cells expressing wild-type CYP2E1 were treated with a stable cAMP analogue, indicating that for CYP2E1 phosphorylation does not seem to play a role in the mitochondrial targeting.3

In conclusion, when SRP binding to the hydrophobic NH2-terminal transmembrane domain of CYP2E1 is compromised, protein translation is not arrested and the entire CYP2E1 protein is translated in the cytosol. A mitochondrial targeting signal located between amino acid residues 74 and 95 is being exposed, probably after binding of the translated CYP2E1 protein with cytosolic chaperones, and the protein is targeted to the mitochondria. The mitochondrial targeting and import of Delta (2-29)2E1 is strongly dependent on the presence of positively charged amino acid residues Arg-75 and Arg-76 and Lys-84 and Lys-87 and of a hydrophobic region between residues 76 and 82. After mitochondrial import the signal sequence of Delta (2-29)2E1 is removed in the mitochondrial matrix, thereby forming the mature soluble and catalytically active protein Delta 2E1.


    ACKNOWLEDGEMENT

We thank Prof. Rita Bernhardt for the generous gift of adrenodoxin and adrenodoxin reductase.


    FOOTNOTES

* This work was supported by grants from the Swedish Medical Research Council and AstraZeneca.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Div. of Molecular Toxicology, Inst. of Environmental Medicine, Karolinska Institutet, Box 210, S-171 77 Stockholm, Sweden. Tel.: 46-8-7287735; Fax: 46-8-337327; E-mail: magnus.ingelman-sundberg@imm.ki.se.

Published, JBC Papers in Press, December 22, 2000, DOI 10.1074/jbc.M008640200

2 The numbering of the amino acids corresponds to that of the full-length CYP2E1.

3 E. P. A. Neve and M. Ingelman-Sundberg, unpublished observations.


    ABBREVIATIONS

The abbreviations used are: TOM, translocase of the outer membrane; ER, endoplasmic reticulum; P450, cytochrome P450; SRP, signal recognition particle; TIM, translocase of the inner membrane; mHsp70, mitochondrial heat shock protein 70; Adx, adrenodoxin; AdR, adrenodoxin reductase.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Neupert, W. (1997) Annu. Rev. Biochem. 66, 863-917[CrossRef][Medline] [Order article via Infotrieve]
2. Mori, M., and Terada, K. (1998) Biochim. Biophys. Acta 1403, 12-27[Medline] [Order article via Infotrieve]
3. Voos, W., Martin, H., Krimmer, T., and Pfanner, N. (1999) Biochim. Biophys. Acta 1422, 235-254[Medline] [Order article via Infotrieve]
4. Pfanner, N. (2000) Curr. Biol. 10, R412-R415[CrossRef][Medline] [Order article via Infotrieve]
5. Pfanner, N., Hoeben, P., Tropschug, M., and Neupert, W. (1987) J. Biol. Chem. 262, 14851-14854[Abstract/Free Full Text]
6. Lee, C. M., Sedman, J., Neupert, W., and Stuart, R. A. (1999) J. Biol. Chem. 274, 20937-20942[Abstract/Free Full Text]
7. von Heijne, G. (1986) EMBO J. 5, 1335-1342[Abstract]
8. Roise, D., and Schatz, G. (1988) J. Biol. Chem. 263, 4509-4511[Free Full Text]
9. Ramage, L., Junne, T., Hahne, K., Lithgow, T., and Schatz, G. (1993) EMBO J. 12, 4115-4123[Abstract]
10. Brix, J., Dietmeier, K., and Pfanner, N. (1997) J. Biol. Chem. 272, 20730-20735[Abstract/Free Full Text]
11. Komiya, T., Rospert, S., Koehler, C., Looser, R., Schatz, G., and Mihara, K. (1998) EMBO J. 17, 3886-3898[Abstract/Free Full Text]
12. Bauer, M. F., Sirrenberg, C., Neupert, W., and Brunner, M. (1996) Cell 87, 33-41[Medline] [Order article via Infotrieve]
13. Bauer, M. F., Hofmann, S., Neupert, W., and Brunner, M. (2000) Trends Cell Biol. 10, 25-31[CrossRef][Medline] [Order article via Infotrieve]
14. Bohni, P. C., Daum, G., and Schatz, G. (1983) J. Biol. Chem. 258, 4937-4943[Abstract/Free Full Text]
15. Hawlitschek, G., Schneider, H., Schmidt, B., Tropschug, M., Hartl, F. U., and Neupert, W. (1988) Cell 53, 795-806[Medline] [Order article via Infotrieve]
16. Sakaguchi, M., Mihara, K., and Sato, R. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 3361-3364[Abstract]
17. Monier, S., Van, L.uc, P., Kreibich, G., Sabatini, D. D., and Adesnik, M. (1988) J. Cell Biol. 107, 457-470[Abstract]
18. Ahn, K., Szczesna-Skorupa, E., and Kemper, B. (1993) J. Biol. Chem. 268, 18726-18733[Abstract/Free Full Text]
19. Murakami, K., Mihara, K., and Omura, T. (1994) J. Biochem. (Tokyo) 116, 164-175[Abstract]
20. Szczesna-Skorupa, E., Chen, C. D., and Kemper, B. (2000) Arch. Biochem. Biophys. 374, 128-136[CrossRef][Medline] [Order article via Infotrieve]
21. Szczesna-Skorupa, E., and Kemper, B. (2000) J. Biol. Chem. 275, 19409-19415[Abstract/Free Full Text]
22. Ogishima, T., Okada, Y., and Omura, T. (1985) J. Biochem. (Tokyo) 98, 781-791[Abstract]
23. Omura, T., and Ito, A. (1991) Methods Enzymol. 206, 75-81[Medline] [Order article via Infotrieve]
24. Ronis, M. J. J., Lindros, K. O., and Ingelman-Sundberg, M. (1996) in Cytochromes P450 Metabolic and Toxicological Aspects (Ioannides, C., ed) , pp. 211-239, CRC Press, Inc., New York
25. Bondoc, F. Y., Bao, Z., Hu, W. Y., Gonzalez, F. J., Wang, Y., Yang, C. S., and Hong, J. Y. (1999) Biochem. Pharmacol. 58, 461-463[CrossRef][Medline] [Order article via Infotrieve]
26. Chen, Q., and Cederbaum, A. I. (1998) Mol. Pharmacol. 53, 638-648[Abstract/Free Full Text]
27. Ingelman-Sundberg, M., Johansson, I., Yin, H., Terelius, Y., Eliasson, E., Clot, P., and Albano, E. (1993) Alcohol 10, 447-452[CrossRef][Medline] [Order article via Infotrieve]
28. French, S. W., Morimoto, M., Reitz, R. C., Koop, D., Klopfenstein, B., Estes, K., Clot, P., Ingelman-Sundberg, M., and Albano, E. (1997) J. Nutr. 127, 907S-911S[Medline] [Order article via Infotrieve]
29. Ronis, M. J., Johansson, I., Hultenby, K., Lagercrantz, J., Glaumann, H., and Ingelman-Sundberg, M. (1991) Eur. J. Biochem. 198, 383-389[Abstract]
30. Pahan, K., Smith, B. T., Singh, A. K., and Singh, I. (1997) Free Radical Biol. Med. 23, 963-971[CrossRef][Medline] [Order article via Infotrieve]
31. Neve, E. P. A., Eliasson, E., Pronzato, M. A., Albano, E., Marinari, U., and Ingelman-Sundberg, M. (1996) Arch. Biochem. Biophys. 333, 459-465[CrossRef][Medline] [Order article via Infotrieve]
32. Eliasson, E., and Kenna, J. G. (1996) Mol. Pharmacol. 50, 573-582[Abstract]
33. Neve, E. P. A., and Ingelman-Sundberg, M. (2000) J. Biol. Chem. 275, 17130-17135[Abstract/Free Full Text]
34. Neve, E. P. A., and Ingelman-Sundberg, M. (1999) FEBS Lett. 460, 309-314[CrossRef][Medline] [Order article via Infotrieve]
35. Hettema, E. H., Distel, B., and Tabak, H. F. (1999) Biochim. Biophys. Acta 1451, 17-34[Medline] [Order article via Infotrieve]
36. Marks, M. S., Ohno, H., Kirchhausen, T., and Bonifacino, J. S. (1997) Trends Cell Biol. 7, 124-128[CrossRef]
37. Schleiff, E., Heard, T. S., and Weiner, H. (1999) FEBS Lett. 461, 9-12[CrossRef][Medline] [Order article via Infotrieve]
38. Abe, Y., Shodai, T., Muto, T., Mihara, K., Torii, H., Nishikawa, S., Endo, T., and Kohda, D. (2000) Cell 100, 551-560[Medline] [Order article via Infotrieve]
39. Ito, A. (1999) Biochem. Biophys. Res. Commun. 265, 611-616[CrossRef][Medline] [Order article via Infotrieve]
40. Walter, P., and Johnson, A. E. (1994) Annu. Rev. Cell Biol. 10, 87-119[CrossRef]
41. Addya, S., Anandatheerthavarada, H. K., Biswas, G., Bhagwat, S. V., Mullick, J., and Avadhani, N. G. (1997) J. Cell Biol. 139, 589-599[Abstract/Free Full Text]
42. Anandatheerthavarada, H. K., Biswas, G., Mullick, J., Sepuri, N. B., Otvos, L., Pain, D., and Avadhani, N. G. (1999) EMBO J. 18, 5494-5504[Abstract/Free Full Text]
43. Eliasson, E., Johansson, I., and Ingelman-Sundberg, M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3225-3229[Abstract]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.